Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neoplasms 3Gastrointestinal Stromal Tumors 3Carcinoma, Renal Cell 3Osteosarcoma 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Adenoma, Islet Cell 2Solid Tumors Refractory to Standard Therapy 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Metastatic Digestive System Neuroendocrine Tumor G1 1Meningioma 1Kidney Neoplasms 1Gastrointestinal Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Carcinoid Tumor 1

Interventions

lutetium Lu 177 dotatate 1cabozantinib 1Sunitinib 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Metastatic Digestive System Neuroendocrine Tumor G1 × Sunitinib × Clear all
NCT05773274 2026-06-03

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
100 enrolled
EndocrineNET

Metastatic Digestive System Neuroendocrine Tumor G1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡